Outlook Therapeutics, Inc.
NASDAQ:OTLKBiotechnology
-$0.10 today
- Market cap
- $99.30M
- Beta
- 0.98
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.74
Volume 4.42M
Average 17.46M
OTLK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Outlook Therapeutics, Inc.NASDAQ: OTLK
Stock-Based Compensation · Q2 FY2026 · quarter ended Mar 2026
Stock-based compensation declines year over year
Q2 FY2026 stock-based compensation of $757.48K fell 56.0% year over year, behind the -37.3% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 14.0% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.
Context
- Stock-based compensation amounted to 629.5% of revenue in FY2025.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -56.0% toward the trailing-twelve-month pace of -37.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 8.9M USD
- Year-over-year change
- +65.2%
- 4-year CAGR
- +16.2%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 8.9M | +65.2% |
| FY2024 | 2024-09-30 | 5.39M | -2.9% |
| FY2023 | 2023-09-30 | 5.55M | -28.1% |
| FY2022 | 2022-09-30 | 7.71M | +57.8% |
| FY2021 | 2021-09-30 | 4.89M | — |
Stock-Based Compensation vs competitors
How OTLK compares with its peers on the latest reported figures
- OTLK's LTM Mar 2026 stock-based compensation of $5.14M is the 3rd largest of the 9 companies compared; the peer median is $3.09M.
- Its year-over-year change of -37.3% is the 6th highest of 9, against a peer median of -29.9%.
- Stock-based compensation amounts to 1543.3% of revenue for OTLK, versus a peer median of 17.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $4.27B | +453006.6% | — | — |
| LTM Mar 2026 | $5.86M | -50.8% | -13.8% | — | |
| LTM Mar 2026 | $5.14M | -37.3% | +4.9% | 1543.3% | |
| LTM Jun 2026 | $3.79M | -50.8% | -5.5% | 18.1% | |
| LTM Mar 2026 | $3.45M | -44.6% | -20.7% | 10.6% | |
| LTM Mar 2026 | $2.72M | -37.2% | -10.8% | — | |
| LTM Mar 2026 | $2.63M | -22.6% | -21.7% | — | |
| LTM Mar 2026 | $1.82M | +13.4% | — | 128.8% | |
| LTM Mar 2026 | $367K | +43.4% | -60.2% | 16.0% | |
| Peer median (excluding OTLK) | $3.09M | -29.9% | -17.2% | 17.0% | |
Competitors are the stored peer set for OTLK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (53.16M) | (66.05M) | (58.98M) | (75.37M) | (62.42M) |
| Depreciation & Amortization | 262.14K | 204.69K | 44.19K | 113.86K | 117.05K |
| Deferred Income Tax | 498.49K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.89M | 7.71M | 5.55M | 5.39M | 8.9M |
| Change in Working Capital | (7.08M) | (1.68M) | 4.75M | (3.02M) | 4.86M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (1.49M) |
| Inventory | 0 | 0 | 0 | 0 | (3.34M) |
| Accounts Payables | (198.47K) | 1.3M | 3.08M | 1.39M | 1.67M |
| Other Working Capital | (6.88M) | (2.98M) | 1.67M | (4.41M) | 8.02M |
| Other Non-Cash Items | 341.55K | 3.15M | 5.66M | 4.09M | 1.58T |
| Operating Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (3) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 6.31M | (2.32M) | 19.77M | (4.27K) | (3.04M) |
| Common Stock Issued | 46.3M | 62.31M | 30.02M | 60.33M | 48.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.59M | (394.15K) | (823.89K) | 0 | 44.98T |
| Financing Cash Flow | 56.19M | 59.59M | 48.97M | 60.33M | 44.98M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 1.94M | 2.92M | 6M | (8.46M) | (6.84M) |
| Free Cash Flow | (54.25M) | (56.67M) | (42.97M) | (68.79M) | (51.83M) |
Outlook Therapeutics, Inc.
NASDAQ:OTLK
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.